23andMe hit with class-action lawsuit; Glass Dx tools with trained honeybees help spot cancer;

> 23andMe now faces a class-action lawsuit claiming the company misled customers by selling genetic tests with no real scientific value. Story

> Roche ($RHHBY) is launching a new lab instrument for high-volume processing of molecular diagnostic samples. Item

> A University of Toronto spinout nailed down $18.8 million in a Series B financing that will help advance its rapid-use molecular diagnostic technology in the U.S. Story

> A new blood test can detect a person's risk of infection from a drop of blood within minutes, according to a study published in the journal Technology. Story

> A Portuguese designer has developed a series of glass diagnostic tools that use trained honeybees to determine if a patient has cancer. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.